Myeloablative Conditioning for Allo-HCT Results in Superior Disease-Free Survival for AML and MDS With Low/Intermediate Disease Risk Index
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Biology of Blood and Marrow Transplantation
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Myeloablative Conditioning for Allogeneic Transplantation Results in Superior Disease-Free Survival for Acute Myeloid Leukemia and Myelodysplastic Syndromes With Low/Intermediate, But Not High Disease Risk Index: A CIBMTR Study: Superior DFS With MAC Compared to RIC HCT in AML/MDS With Low/Intermediate Risk DRI
Biol. Blood Marrow Transplant 2020 Sep 30;[EPub Ahead of Print], N Bejanyan, M Zhang, K Bo-Subait, C Brunstein, H Wang, ED Warlick, S Giralt, T Nishihori, R Martino, J Passweg, A Dias, E Copelan, G Hale, RP Gale, M Solh, MA Kharfan-Dabaja, MA Diaz, S Ganguly, S Gore, LF Verdonck, NM Hossain, N Kekre, B Savani, M Byrne, C Kanakry, MS Cairo, S Ciurea, HC Schouten, C Bredeson, R Munker, H Lazarus, JY Cahn, M van Der Poel, D Rizzieri, JA Yared, C Freytes, J Cerny, M Aljurf, ND Palmisiano, A Pawarode, VU Bacher, MR Grunwald, S Nathan, B Wirk, GC Hildebrandt, S Seo, RF Olsson, B George, M de Lima, CS Hourigan, B Sandmaier, M Litzow, P Kebriaei, W Saber, D WeisdorfFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.